PURPOSE: To evaluate the correlations between the apparent diffusion coefficient (ADC) value and the standardized uptake value (SUV) with prognostic factors in @entity0 . MATERIALS AND METHODS: Seventy @entity1 with @entity0 (56 cases of @entity513 , four of mixed @entity1137 , three of lobular invasive @entity189 , two of @entity189 , and one each of mixed @entity513 , @entity189 , @entity189 , @entity189 , and @entity420 ) were included in this study. All @entity1 underwent presurgical breast magnetic resonance imaging (MRI) with diffusion-weighted imaging (DWI) at 1.5T and whole-body @entity419 ( @entity419 ) positron emission tomography (PET) / computed tomography (CT). For all invasive @entity0 and @entity513 , we assessed the relationships among ADC, SUV, and pathological prognostic factors. RESULTS: Both the median ADC value and maximum SUV (SUVmax) were significantly associated with @entity1350 (P = 0.008 and P = 0.026, respectively). SUVmax was also significantly correlated with @entity5 size (P = 0.001), histological grade (P = 0.001), lymph node status (P = 0.0015), @entity172 receptor status (P = 0.010), and @entity1 @entity1722 status (P = 0.020), whereas ADC values were not. The correlation between the ADC and SUVmax was not significant (P = 0.356; R = -0.112). @entity189 showed high ADC and relatively low SUVmax. @entity189 showed low ADC and high SUVmax. When we evaluated the relationships among ADC, SUVmax, and prognostic factors in the 56 @entity513 , our statistical results were not significantly changed, except SUVmax was also significantly associated with @entity1420 receptor status (P = 0.034), but not lymph node status. CONCLUSION: SUVmax may be valuable for predicting the prognosis of @entity0 . Both ADC and SUVmax are useful to predict @entity1350 . J. Magn. Reson. Imaging 2015.

Diffusion-weighted imaging and XXXX positron emission tomography/computed tomography in @entity0 : Correlation of the apparent diffusion coefficient and maximum standardized uptake values with prognostic factors.

@entity1 :: ('9606', 'Species') :: ['human', 'women', 'patients'] @entity1137 :: ('MESH:D018275', 'Disease') :: ['ductal and lobular invasive carcinoma'] @entity172 :: ('MESH:D004967', 'Chemical') :: ['estrogen'] @entity0 :: ('MESH:D001943', 'Disease') :: ['invasive breast cancer', 'breast cancer', 'breast cancers'] @entity419 :: ('MESH:D019788', 'Chemical') :: ['(18) F-FDG', '(18) F-fluorodeoxyglucose'] @entity1420 :: ('MESH:D011374', 'Chemical') :: ['progesterone'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor'] @entity189 :: ('MESH:D002277', 'Disease') :: ['metaplastic carcinoma', 'mucinous carcinoma', 'Mucinous carcinoma', 'carcinoma', 'medullary carcinoma', 'micropapillary carcinoma', 'Medullary carcinoma'] @entity1350 :: ('MESH:D019043', 'Disease') :: ['vascular invasion'] @entity513 :: ('MESH:D044584', 'Disease') :: ['invasive ductal carcinoma', 'ductal and mucinous carcinoma', 'invasive ductal carcinomas'] @entity420 :: ('MESH:D000230', 'Disease') :: ['tubular carcinoma'] @entity1722 :: ('2064', 'Gene') :: ['epidermal growth factor receptor 2']
@entity419 :: (MESH:D019788,Chemical) :: ['(18) F-fluorodeoxyglucose']
